Studies whether complement activation signals severity of IgA nephropathy
Observes complement activity as a marker of kidney disease in adults with IgA nephropathy.
Key facts
- Who runs it
- University Hospital, Strasbourg, France
- Where
- Strasbourg, FranceSee the site
- Trial code
- Registry title
- Study of the Link Between Complement Activation and IgA Nephropathy Severity
- Status
- Recruiting
- People taking part
- 400 people, planned
- Started
- 9 May 2022
- Expected to end
- 1 May 2027
- Type of study
- Observational
- Treatments tested
- IgAN patients
- Record updated
- 19 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with IgA nephropathy confirmed by a kidney biopsy. It studies whether complement activation shows how severe the disease is.
- Age
- 18 years and older
- Sex
- Men and women
- Disease stage
- IgA nephropathy confirmed by biopsy. Primary and secondary forms can join, at any date of diagnosis and any level of kidney function.
- Earlier treatment
- People with or without a past kidney transplant can join. People must not be on treatment with complement inhibitors now.
Main reasons for not taking part
- Active or recent infection or inflammation (less than 2 months)
- Recent vaccination (less than 2 months)
- Treatment now for acute humoral rejection
- Plasma exchange treatment (less than 2 months)
- Current treatment with complement inhibitors
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult patients, male or female, with a biopsy proven IgA nephropathy
- Primitive and secondary forms can be included
- Regardless of the date of diagnosis and the level of kidney function
- With or without past of kidney transplantation
- Followed in the Nephrology Department, Strasbourg University Hospital
- Signed informed consent
Who cannot take part
- Active or recent infectious or inflammatory syndrome (<2 months), recent vaccination (<2 months), ongoing acute humoral rejection treatment, treatment with plasma exchanges (<2 months), current treatment with complement inhibitors
- Impossibility of giving informed information (emergency situation, difficulties in understanding, etc.)
- Subject under safeguard of justice, guardianship or curatorship
Where in France
- Service de néphrologieStrasbourg, FranceContact: Sophie Caillard, MDTaking people
About the trial
What the trial wants to find out
ICONE study (IgA Complement and NEphropathy is a prospective monocentric observational study.
Read full original descriptionShow less
The main objective is to evaluate the relevance of complement activation as a biomarker of disease severity and progression in patients with a biopsy proven IgAN.
Treatments tested
- IgAN patients
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study of the Link Between Complement Activation and IgA Nephropathy Severity
- Plain-language title
- Studies whether complement activation signals severity of IgA nephropathyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- Association of Complement Genetics with Outcomes in IgA Nephropathy.Clinical journal of the American Society of Nephrology : CJASN, 2026
- Record updated
- 19 August 2026